Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Other operating expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Danaher

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment is composed of analytical instruments, reagents, consumables, software, and services that hospitals, physicians' offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Danaher exceeds Q1 expectations, eyes growth in China market

Danaher's Q1 performance showcased resilience and strategic focus amidst revenue challenges.
The company's strengths in operational efficiency and strategic initiatives position it well for future growth.
Challenges in certain segments highlight the need for adaptive strategies and market diversification.
Opportunities in China's market recovery and operational improvements offer avenues for sustained growth.

Danaher reports resilient Q2 performance amid COVID-19 challenges

Danaher navigated Q2 2023 with resilience amidst COVID-19 challenges, showcasing strong financial performance and strategic focus. While facing revenue declines in certain segments, the company remains confident in its ability to create shareholder value and improve human health. Capital deployment, inventory management, and market alignment present opportunities for future growth.

Danaher reports Q3 revenue decline, eyes growth in diagnostics market

Danaher's Q3 performance showed revenue declines in key segments, but strategic moves like spin-offs and acquisitions indicate a focus on long-term growth. Challenges in China and revenue projections for the year present short-term hurdles, while opportunities in drug development and diagnostics offer potential for future expansion.

Danaher reports solid 2023 performance, anticipates gradual growth in 2024

Danaher Corporation's 2023 performance showcased strong full-year sales and operating profit margin, but the fourth quarter saw a decline in core revenue. The company is focused on enhancing its portfolio and strengthening its growth trajectory, with expectations for improved growth in the second half of 2024. Challenges include the need for gradual improvement in demand and the pace of recovery in different geographies.

Danaher beats Q1 expectations, eyes growth in Diagnostics segment

Danaher's Q1 2024 performance exceeded expectations, driven by strong Diagnostics segment growth.
While facing challenges in bioprocessing and margin expectations, the company remains focused on long-term sustainability.
Opportunities lie in anticipated growth in Diagnostics and bioprocessing segments, with a focus on innovation and recurring revenue.
Continuous monitoring of market trends and global capabilities position Danaher for future success.

Danaher beats Q2 expectations, eyes growth amid revenue challenges

Danaher Corporation delivered a strong performance in Q2 2024, surpassing revenue, earnings, and cash flow expectations, driven by bioprocessing and Cepheid's success.
While facing challenges such as core revenue declines in the biotechnology segment, the company maintains a solid financial position with strong free cash flow.
Opportunities lie in leveraging positive momentum in key segments, expanding market share, and enhancing sustainability efforts to drive future growth and profitability.
Overall, Danaher's strategic focus on operational efficiency and growth areas positions it well to navigate challenges and capitalize on opportunities in the evolving market landscape.

Danaher surpasses Q3 expectations, eyes China stimulus for growth

Danaher's Q3 performance exceeded expectations, driven by strong results in biotechnology and Cepheid's core revenue growth.
While facing challenges in China market dynamics and core revenue declines in certain segments, the company remains optimistic about future growth.
Opportunities lie in leveraging China's stimulus for 2025 outlook and strategic M&A activities to fuel long-term growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The Environmental and Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Danaher (DHR) benefits from strength across its businesses, acquisitions and shareholder-friendly policies. However, rising costs and expenses remain concerning.

Danaher (DHR) Exhibits Bright Prospects, Headwinds Remain

Danaher (DHR) raises revenue projection for the first quarter of 2021 on strengthening Diagnostics and Life Sciences businesses.

Danaher (DHR) Q1 Revenue Projections Increase, Shares Gain

Danaher (DHR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Danaher (DHR) Surges 3.4%: Is This an Indication of Further Gains?

Sumitomo Corp

SSUMY vs. DHR: Which Stock Is the Better Value Option?

SSUMY vs. DHR: Which Stock Should Value Investors Buy Now?

Shares of Danaher Corp. rose 0.7% in premarket trading Tuesday, after the maker of medical, industrial and commercial products provided an upbeat first-quarter profit outlook. The company said it expects first-quarter core revenue growth to be above the high-end of previously provided guidance.

Danaher stock rises after upbeat revenue outlook

WASHINGTON, April 13, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced today that it expects first quarter 2021 core revenue growth to be above the high-end of the Company's previously communicated guidance range. For the quarter ended April 2, 2021, the Company expects revenue growth to be approximately 57.0% and non-GAAP core revenue growth including Cytiva to be approximately 29.0%.

Danaher Provides Update On First Quarter 2021 Financial Performance

Chipotle

Fastenal

Lowe's

Semtech

Although Friday is set for mixed trading, the indices are set to close the week with solid gains as the S&P continues hovering around a record high. Meanwhile, Q.ai's deep learning algorithms have brought you today's top buys.

Top Stocks To Buy Today As April Keeps Up The Strength

Applied Materials

Caterpillar

Deere & Company

Target

Taiwan Semiconductor Manufacturing

It's certainly a hot market, but sector rotation and consolidation in select sectors means that safe stocks are now the most appealing. The post 7 Safe Stocks to Buy for Uncertain Times appeared first on InvestorPlace.

7 Safe Stocks to Buy for Uncertain Times

With Covid vaccine manufacturing on the upswing, shares of Danaher could gain 20%, according to Citigroup.

Covid Vaccines Are Ramping Up. That Could Fuel Gains For Danaher.

Abercrombie & Fitch

Pfizer

Teva Pharmaceutical

Flexion Therapeutics

Jazz Pharmaceuticals

With the trading day approaching halfway over, the broad markets were trading marginally positive.

Abercrombie, Pfizer, Teva and More of Wednesday Afternoon Analyst Calls

Amplify Treatments Testing & Advancements ETF

Gilead Sciences

Hologic

Immunovant Inc

Health Care Select Sector SPDR Fund

Covid-19 has put healthcare stocks in the limelight. These seven companies should be on your radar for the next pandemic.

7 Healthcare Stocks to Buy to Prepare Your Portfolio For The Next Pandemic

WASHINGTON, March 25, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2021 on Thursday, April 22, 2021 beginning at 8:00 a.m. ET and lasting approximately 1 hour.

Danaher Schedules First Quarter 2021 Earnings Conference Call

BREA, Calif., March 23, 2021 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, today announced that its Access SARS-CoV-2 IgG II antibody assay received U.S. Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration.

Beckman Coulter's SARS-CoV-2 IgG II antibody test receives Emergency Use Authorization from the FDA

AMERISAFE

Avnet

Bank of America

BWX Technologies

CNO Financial Group

CyrusOne

CRA International

CareTrust REIT

Dollar General

Dick's Sporting Goods

Exponent

First Financial Northwest

Comfort Systems USA

First Midwest Bancorp

Fulton Financial

W. R. Grace & Co.

Great Southern Bancorp

Getty Realty

Hackett Group

Hurco Companies

Innovative Industrial Properties

Investar Hhld

Kimball International

A weekly summary of dividend activity for Dividend Challengers. Companies which changed their dividends.

Dividend Challenger Highlights: Week Of March 21

Danaher's 63-month total return is fantastic, beating the Dow 63-month baseline by 138.09%. Last quarter's earnings beat expected results by $0.25 on the bottom line and top line beat with a good gain over last year's results.

Danaher: Great Total Return And Last Quarter Revenues Had Strong Increases

BREA, Calif., March 18, 2021 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, today announced their commitment to support the U.S. government's plan to invest more than $12 billion to expand COVID-19 testing with their high-throughput, high-quality lab antigen test, Access SARS-CoV-2 Ag,* ideal for mass screening testing.

Beckman Coulter Offers $4/High-throughput Antigen Test to Support U.S. Government Initiative to Expand COVID-19 Testing

Amphenol

Chubb

Intercontinental Exchange

International Flavors & Fragrances

Medtronic

Walmart

In this article series, we provide a summary of upcoming ex-dividend dates.

Upcoming Ex-Dividend Dates: March 16-29, 2021

Danaher Corporation (DHR) Management Presents at Barclays Global Healthcare Conference (Transcript)

CORALVILLE, Iowa--(BUSINESS WIRE)--Integrated DNA Technologies (IDT), a leading comprehensive genomics solutions provider, announced today the acquisition of Swift Biosciences, a pioneer in the development of Next-Generation Sequencing (NGS) library preparation genomics kits for academic, translational, and clinical research. IDT is a leader in developing and manufacturing nucleic acid products for academic and commercial research, agriculture, medical diagnostics, pharmaceutical development, a

IDT Acquires Swift Biosciences, a Pioneer in the Development of Next-Generation Sequencing (NGS) Library Preparation Genomics Kits for Academic, Translational, and Clinical Research

DTE Energy

Ironwood Pharma

Nautilus

Primo Water

Sensei Biotherapeutics

LendingTree

There are many reasons an insider might sell. But there is only one reason for insider buying; insiders think the stock will trade higher.

7 Stocks With Significant Insider Buying

WASHINGTON, March 4, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that Executive Vice President and Chief Financial Officer, Matt McGrew, will be presenting at the Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 11:30 a.m. ET. The audio will be...

Danaher To Present At Barclays Global Healthcare Conference

Microsoft

Oracle

Virgin Galactic

Tesla

Adaptive Biotechnologies

Citrix Systems

DocuSign

With the trading day about halfway over, the broad markets have not made up their minds on a direction for the day.

Microsoft, Oracle, Tesla, Virgin Galactic and More Wednesday Afternoon Analyst Calls

News for Danaher Stock (DHR)